These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 21684427)

  • 1. The Vaccine Formulation Laboratory: a platform for access to adjuvants.
    Collin N; Dubois PM
    Vaccine; 2011 Jul; 29 Suppl 1():A37-9. PubMed ID: 21684427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Technology transfer of an oil-in-water vaccine-adjuvant for strengthening pandemic influenza preparedness in Indonesia.
    Ventura R; Brunner L; Heriyanto B; de Boer O; O'Hara M; Huynh C; Suhardono M; Collin N
    Vaccine; 2013 Mar; 31(12):1641-5. PubMed ID: 22884665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. WHO initiative to increase global and equitable access to influenza vaccine in the event of a pandemic: supporting developing country production capacity through technology transfer.
    Friede M; Palkonyay L; Alfonso C; Pervikov Y; Torelli G; Wood D; Kieny MP
    Vaccine; 2011 Jul; 29 Suppl 1():A2-7. PubMed ID: 21684422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Establishment of pandemic influenza vaccine production capacity at Bio Farma, Indonesia.
    Suhardono M; Ugiyadi D; Nurnaeni I; Emelia I
    Vaccine; 2011 Jul; 29 Suppl 1():A22-5. PubMed ID: 21684423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Technology transfer of oil-in-water emulsion adjuvant manufacturing for pandemic influenza vaccine production in Romania.
    Fox CB; Huynh C; O'Hara MK; Onu A
    Vaccine; 2013 Mar; 31(12):1633-40. PubMed ID: 23103197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. WHO influenza vaccine technology transfer initiative: role and activities of the Technical Advisory Group.
    Francis DP; Grohmann G
    Vaccine; 2011 Jul; 29 Suppl 1():A45-7. PubMed ID: 21684429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Domestic influenza vaccine production in Mexico: a state-owned and a multinational company working together for public health.
    Ponce-de-Leon S; Velazquez-Fernandez R; Bugarin-González J; García-Bañuelos P; Lopez-Sotelo A; Jimenez-Corona ME; Padilla-Catalan F; Cervantes-Rosales R
    Vaccine; 2011 Jul; 29 Suppl 1():A26-8. PubMed ID: 21684424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. United States of America Department of Health and Human Services support for advancing influenza vaccine manufacturing in the developing world.
    Perdue ML; Bright RA
    Vaccine; 2011 Jul; 29 Suppl 1():A48-50. PubMed ID: 21684430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modern Vaccines/Adjuvants Formulation--Session 2 (Plenary II): May 15-17, 2013--Lausanne, Switzerland.
    Collin N
    Hum Vaccin Immunother; 2013 Sep; 9(9):2015-6. PubMed ID: 23966098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modern Vaccines/Adjuvants Formulation Session 6: Vaccine &Adjuvant Formulation & Production 15-17 May 2013, Lausanne, Switzerland.
    Fox CB
    Hum Vaccin Immunother; 2013 Sep; 9(9):2007-8. PubMed ID: 23787558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of pandemic influenza vaccine production capacity in Viet Nam.
    Hoa LK; Hiep LV; Be LV
    Vaccine; 2011 Jul; 29 Suppl 1():A34-6. PubMed ID: 21684426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Live attenuated pandemic influenza vaccine: clinical studies on A/17/California/2009/38 (H1N1) and licensing of the Russian-developed technology to WHO for pandemic influenza preparedness in developing countries.
    Rudenko L; van den Bosch H; Kiseleva I; Mironov A; Naikhin A; Larionova N; Bushmenkov D
    Vaccine; 2011 Jul; 29 Suppl 1():A40-4. PubMed ID: 21684428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influenza vaccine production for Brazil: a classic example of successful North-South bilateral technology transfer.
    Miyaki C; Meros M; Precioso AR; Raw I
    Vaccine; 2011 Jul; 29 Suppl 1():A12-5. PubMed ID: 21684420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An international technology platform for influenza vaccines.
    Hendriks J; Holleman M; de Boer O; de Jong P; Luytjes W
    Vaccine; 2011 Jul; 29 Suppl 1():A8-11. PubMed ID: 21684431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Influenza vaccine: globalization of public health stakes].
    Collin N; Briand S
    Med Trop (Mars); 2009 Aug; 69(4):322. PubMed ID: 19725377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New horizons in adjuvants for vaccine development.
    Reed SG; Bertholet S; Coler RN; Friede M
    Trends Immunol; 2009 Jan; 30(1):23-32. PubMed ID: 19059004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of influenza vaccine production capacity by the Government Pharmaceutical Organization of Thailand: addressing the threat of an influenza pandemic.
    Surichan S; Wirachwong P; Supachaturas W; Utid K; Theerasurakarn S; Langsanam P; Lakornrach P; Nitisaporn L; Chansikkakorn C; Vangkanonta W; Kaweepornpoj R; Poopipatpol K; Thirapakpoomanunt S; Srichainak S; Artavatkun W; Chokevivat V; Wibulpolprasert S
    Vaccine; 2011 Jul; 29 Suppl 1():A29-33. PubMed ID: 21684425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Technology transfer hub for pandemic influenza vaccine.
    Friede M; Serdobova I; Palkonyay L; Kieny MP
    Vaccine; 2009 Jan; 27(5):631-2. PubMed ID: 19022316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pulmonary vaccine delivery.
    Lu D; Hickey AJ
    Expert Rev Vaccines; 2007 Apr; 6(2):213-26. PubMed ID: 17408371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fourth International Conference: Modern Vaccines/Adjuvants Formulation--Impact on Future Development: May 15-17 2013, CHUV, Lausanne, Switzerland.
    Tupin E
    Hum Vaccin Immunother; 2013 Sep; 9(9):2009-12. PubMed ID: 23896583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.